Last reviewed · How we verify
Tetravalent Vaccine
A tetravalent vaccine stimulates the immune system to produce antibodies and cellular immunity against four distinct pathogenic targets or strains.
A tetravalent vaccine stimulates the immune system to produce antibodies and cellular immunity against four distinct pathogenic targets or strains. Used for Protection against four dengue serotypes (dengue tetravalent vaccine).
At a glance
| Generic name | Tetravalent Vaccine |
|---|---|
| Also known as | Gardasil |
| Sponsor | Instituto Nacional de Salud Publica, Mexico |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Tetravalent vaccines contain antigens from four different disease agents or variants, triggering both humoral (antibody) and cell-mediated immune responses. This approach provides broader protection by targeting multiple circulating strains or related pathogens simultaneously, reducing the likelihood of infection across the covered serotypes or variants.
Approved indications
- Protection against four dengue serotypes (dengue tetravalent vaccine)
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
- Headache
Key clinical trials
- Vaccine Pandemic Preparedness Through Airway Immunology Characterization (EARLY_PHASE1)
- A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia (PHASE4)
- Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (PHASE1)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge (PHASE1)
- Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). (PHASE1, PHASE2)
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases (PHASE4)
- A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetravalent Vaccine CI brief — competitive landscape report
- Tetravalent Vaccine updates RSS · CI watch RSS
- Instituto Nacional de Salud Publica, Mexico portfolio CI